Vor Biopharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 168
- Market Cap
- $60.8M
- Introduction
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
CAR-T Cell Therapy Funding Surges to $141.2 Billion as Industry Expands Globally
• The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals.
• More than 170 companies worldwide are developing CAR-T products with 1,944 therapies in development, while 13 CAR-T cell therapies have received regulatory approval globally since 2017.
• Despite a slowdown in IPOs and M&A activity in 2024, venture capital funding remains strong with 89 CAR-T companies securing $7.7 billion since 2014, supporting advancement in both blood cancer and solid tumor applications.
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
• DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
• Several major pharmaceutical companies including BeiGene, Celgene, Hoffmann-La Roche, and Allogene Therapeutics have initiated pivotal late-stage clinical trials for novel B-cell lymphoma treatments in March 2025.
• Emerging therapies include CAR-T cell approaches, bispecific antibodies, and novel targeted agents, with many incorporating dual-targeting mechanisms to overcome resistance seen with single-target therapies.
United Therapeutics Completes Enrollment in Phase 3 TETON 1 IPF Trial of Inhaled Treprostinil
• United Therapeutics has fully enrolled its Phase 3 TETON 1 study, evaluating nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis (IPF).
• The TETON 1 trial, with 598 patients across the U.S. and Canada, is part of a larger program assessing inhaled treprostinil in IPF and progressive pulmonary fibrosis (PPF).
• Top-line data from the TETON 1 study is anticipated in the first half of 2026, potentially leading to a new treatment option for IPF patients.
• If successful, United Therapeutics plans to seek FDA approval to expand Tyvaso's label to include IPF, and pursue European marketing authorization.
BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies
• BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
• The company plans to initiate additional trials combining BNT327/PM8002 with antibody-drug conjugates (ADCs) in 2025, expanding its combination strategy.
• BioNTech's mRNA cancer immunotherapy, autogene cevumeran, is being evaluated in a Phase 2 trial for muscle-invasive urothelial carcinoma in combination with nivolumab.
• Clinical data readouts are expected in 2025 and 2026 from multiple randomized trials of personalized and off-the-shelf mRNA cancer immunotherapy candidates.
CAR-T Cell Therapy Industry Surges to $141.2 Billion in Funding as Clinical Success Drives Investment
• The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with potential total value reaching $281.7 billion when including undisclosed deals.
• Since 2014, 89 CAR-T companies have secured $7.7 billion in venture capital funding, while 42 companies have raised $6.4 billion through IPOs, demonstrating sustained investor confidence.
• Despite a slowdown in M&A activity in 2024, the sector continues to expand with 170+ companies developing 1,944 therapies, including 244 trials targeting solid tumors beyond the current blood cancer focus.
Vor Biopharma Announces Positive Data and New CD45 ADC Program, Analysts See Significant Upside
• Vor Biopharma reported updated Phase 1/2 VBP101 study results showing promising relapse-free survival data in AML/MDS patients, exceeding historical benchmarks.
• Initial PK data for VCAR33ALLO demonstrated in vivo expansion at the lowest dose, with dose escalation planned, indicating potential efficacy.
• The company is developing a new CD45 ADC program (VADC45) for conditioning regimens, offering a fast path to commercial development and partnership opportunities.
• Analysts maintain an Outperform rating with a price target of US$11.00, citing significant upside potential from trem-cel and CD45-based depletion approaches.
© Copyright 2025. All Rights Reserved by MedPath